Journal
ANTIVIRAL RESEARCH
Volume 129, Issue -, Pages 93-98Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2016.03.001
Keywords
Iminosugar; UV-4B; Dengue; Antibody-dependent enhancement; Antiviral; Glucosidase
Categories
Funding
- NIAID [HHSN272201100030C]
- Oxford Glycobiology Institute Endowment
- Emergent BioSolutions
- Lerner-Fink Fellowship in Medicinal Chemistry
- Wellcome Trust [097300/Z/11/Z, 105402/Z/14/Z]
- Wellcome Trust [097300/Z/11/Z, 105402/Z/14/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
The antiviral activity of UV-4 was previously demonstrated against dengue virus serotype 2 (DENV2) in multiple mouse models. Herein, step-wise minimal effective dose and therapeutic window of efficacy studies of UV-4B (UV-4 hydrochloride salt) were conducted in an antibody-dependent enhancement (ADE) mouse model of severe DENV2 infection in AG129 mice lacking types I and II interferon receptors. Significant survival benefit was demonstrated with 10-20 mg/kg of UV-4B administered thrice daily (TID) for seven days with initiation of treatment up to 48 h after infection. UV-4B also reduced infectious virus production in in vitro antiviral activity assays against all four DENV serotypes, including clinical isolates. A set of purified enzyme, in vitro, and in vivo studies demonstrated that inhibition of endoplasmic reticulum (ER) alpha-glucosidases and not the glycosphingolipid pathway appears to be responsible for the antiviral activity of UV-4B against DENV. Along with a comprehensive safety package, these and previously published data provided support for an Investigational New Drug (IND) filing and Phases 1 and 2 clinical trials for UV-4B with an indication of acute dengue disease. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available